||EPS - Basic
||Market Cap (m)
BTG Share Discussion Threads
Showing 4176 to 4196 of 4200 messages
|BTG plc (BTG) Upgraded to “Buy” at Numis Securities Ltd
Posted by Trent Williams on Oct 17th, 2016 // No Comments
BTG plc logoBTG plc (LON:BTG) was upgraded by equities researchers at Numis Securities Ltd to a “buy” rating in a research note issued on Monday. The firm currently has a GBX 900 ($11.14) price target on the stock. Numis Securities Ltd’s target price points to a potential upside of 29.87% from the stock’s previous close.|
|biotec flying in USA yesterday .Surprised no pull through here today.|
|Oh thanks I see it now .|
|It's on the news section for today.A software certification for aiding Therasphere.|
|Is it on the BTG website.|
|Another brick in the competency wall today. Credibility with the academic community grows.Now that's how to grow a business!Well done the Therasphere team.|
|Share of the week
|The henny-penny theory of investment does not seem to be working here. It never makes sense with a solid company like BTG to rush about the street shouting "The sky is falling" when the share price drops. Much better to take the opportunity to buy. CT's (and others') gloomy prognostications seem to have been completely wrong again.|
|A balanced piece in the Telegraph today rather unfortunately headed "Inside KTG!"listing pros and cons|
|Does the cash from the settlement for the claim against Biocompatibles come from BTG or from the previous owners and their insurers ?|
|Oh dear - Tempus is having a bad day!
Having previously been a fan of BTG, 'Tempus' (The Times) now says "On 36 times earnings, I would wait for a further period of price weakness to buy" and concludes "Avoid - long term picture is good but multiple looks high".
This seams a bit contrarian given that I am sure Tempus has recommended to buy BTG at higher multiples/higher share price before, perhaps he has been influenced by CT!
To to fair, I think Tempus is having a bad day because he also recommends buying BAE (despite its insane pension deficit) and buying DFS (despite the fact that they just sell ... er ... Sofas!).
I think he should go and lie down in a darkened room for a bit.|
|The broker reports will follow shortly , will the £7 hold Captain.|
|I agree gregmorg.
Other good quotes from the article that CT kindly referred to us (thanks CT) include - "the good news is that this product works extraordinarily well. There is not a patient that we're aware of who hasn't responded well" & 'Day by day, BTG sees more physicians using Varithena'.
It has been very very slow, but perhaps there are some nascent signs of the success of Varithens.|
|£3 by Xmas, then? LOL|
|Good news ref lc bead. Still not convinced ref varithena.|
|All cash in the bank.I wonder if the next bolt on might be sterling based.Any candidates?|
|CT - if Varithena sales hit £2m, if my memory serves me correctly, that would be a near doubling of sales!! So I think it will be less than that, BUT I still don't quite get your point as BTG have maintained all along the 2016-2017 will be an inflexion point, from static sales to growing sales, the bigger growth numbers as I understand it are not anticipated until 2017-2018 and beyond.
BTG clearly still believe in Varithena, check out Louise's comments in the recent magazine article, I though they were encouraging. And, they are investing in a Canadian launch - why bother wth that if the product is floundering?
All in all, I think this is the best news we could have anticipated. I'm happy.|
|If unsure then?|
|Will not surprise me if varithena revenue for first half is less than £2m.
And what about expiry of Btg patent in dec 2016 on abiraterone? The combination patent out until 2026 is owned by j&j.|
|Also Varithena also ready for uptake in Canada , so though it is slow it is starting to gain coverage.
Overall a steady set of results , giving the company the strength to do an earning enhancing deal in the near term .|